Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced that Arthur T. Sands, M.D., Ph.D., the company's CEO, will participate in two key conferences in March 2022. The 32nd Annual Oppenheimer Healthcare Conference is scheduled for March 15 at 4:00 p.m. ET, and the 2nd Guggenheim Targeted Protein Degradation Day will take place on March 16 at 11:00 a.m. ET. Both events will be available via live webcast and archived on the Nurix website for 30 days.

SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in March:

• 32nd Annual Oppenheimer Healthcare Conference
  Presentation: Tuesday, March 15 at 4:00–4:30 p.m. ET
• 2nd Guggenheim Targeted Protein Degradation Day
  Fireside chat: Wednesday, March 16, at 11:00–11:30 a.m. ET

The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For more information, please visit http://www.nurixtx.com.

Contacts:

Investors:	Media:
Elizabeth Wolffe, Ph.D.	Brett Whelan
Wheelhouse Life Science Advisors	LifeSci Communications
lwolffe@wheelhouselsa.com	bwhelan@lifescicomms.com

FAQ

What conferences will Nurix Therapeutics participate in March 2022?

Nurix Therapeutics will participate in the 32nd Annual Oppenheimer Healthcare Conference on March 15, and the 2nd Guggenheim Targeted Protein Degradation Day on March 16.

What is the date and time of the Oppenheimer Healthcare Conference presentation by Nurix?

The presentation at the Oppenheimer Healthcare Conference is scheduled for March 15, 2022, from 4:00 to 4:30 p.m. ET.

When is the Guggenheim Targeted Protein Degradation Day event for Nurix?

The Guggenheim Targeted Protein Degradation Day will be held on March 16, 2022, at 11:00 a.m. ET.

Where can I access the live webcasts of Nurix’s conference presentations?

The live webcasts of Nurix’s conference presentations can be accessed on the Investors section of the Nurix website.

How long will the archived webcasts of Nurix's events be available?

The archived webcasts of Nurix's events will be available for approximately 30 days after each event.